Teva Pharma (TEVA) Gets a Hold Rating from Credit Suisse


Credit Suisse analyst Vamil Divan maintained a Hold rating on Teva Pharma (TEVA) yesterday and set a price target of $26. The company’s shares closed yesterday at $19.02.

According to TipRanks.com, Divan is a 1-star analyst with an average return of -3.2% and a 42.9% success rate. Divan covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Aimmune Therapeutics, and Johnson & Johnson.

Teva Pharma has an analyst consensus of Hold, with a price target consensus of $24.33.

See today’s analyst top recommended stocks >>

The company has a one-year high of $25.96 and a one-year low of $16.35. Currently, Teva Pharma has an average volume of 11.63M.

Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which engages in development, production and marketing of drugs, generic drugs, over-the-counter drugs, active ingredients for the pharmaceutical industry (APIs) and therapeutic products. It operates through two segments: Generic Medicines and Specialty Medicines.

Read More on TEVA:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts